word
count
text
word
count
ccbynd
intern
licens
made
avail
abstract
vaccin
efficaci
suscept
infect
ve
regardless
symptom
import
endpoint
vaccin
trial
pathogen
high
proport
asymptomat
infect
infect
may
contribut
onward
transmiss
outcom
congenit
zika
syndrom
howev
estim
ve
resourceintens
aim
identifi
method
accur
estim
ve
limit
inform
avail
resourc
constrain
model
individu
random
vaccin
trial
gener
network
individu
simul
epidem
diseas
natur
histori
follow
suscept
expos
infecti
symptomat
infecti
asymptomat
recov
model
use
seven
approach
estim
ve
also
estim
vaccin
efficaci
progress
symptom
vep
correct
rel
risk
interv
censor
cox
model
accur
estim
ve
requir
serolog
test
particip
cox
model
use
symptomat
infect
return
bias
estim
acquir
serolog
endpoint
sampl
imput
remain
infect
status
yield
unbias
ve
estim
across
valu
accur
estim
vep
higher
valu
identifi
resourcepreserv
method
accur
estim
ve
import
design
trial
diseas
high
proport
asymptomat
infect
world
health
organ
identifi
list
prioriti
pathogen
potenti
caus
futur
public
health
emerg
intern
concern
coalit
epidem
prepared
innov
cepi
dedic
one
billion
dollar
vaccin
develop
effort
start
three
middl
east
respiratori
syndrom
mer
coronaviru
lassa
viru
nipah
viru
three
pathogen
well
other
list
zika
viru
high
proport
asymptomat
mild
infect
vaccin
efficaci
suscept
infect
ve
regardless
symptom
level
import
endpoint
vaccin
trial
pathogen
infect
may
contribut
onward
transmiss
outcom
congenit
zika
syndrom
even
without
primari
symptom
howev
ve
resourceintens
estim
requir
test
trial
particip
either
period
conduct
assay
infect
throughout
trial
serolog
test
trial
conclus
natur
vaccinederiv
immun
respons
distinguish
test
trial
particip
also
necessari
estim
vaccin
efficaci
progress
vep
symptom
anoth
critic
outcom
measur
note
analysi
dengu
vaccin
trial
result
protect
symptomat
infect
may
gener
differ
protect
infect
case
dengu
vep
may
neg
due
antibodi
depend
enhanc
therefor
import
consid
estim
ve
vep
analyz
trial
result
aim
identifi
methodolog
accur
estim
ve
vep
limit
amount
inform
avail
resourc
time
money
constrain
throughout
use
asymptomat
synonym
subclin
mean
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
infect
episod
gener
suffici
symptom
prompt
test
would
reveal
particip
current
infect
caus
pathogen
model
vaccin
trial
first
gener
model
main
popul
network
individu
group
commun
structur
describ
previous
see
supplementari
tabl
paramet
model
compartment
use
determinist
differenti
equat
dynam
main
popul
stochast
dynam
commun
simul
epidem
main
popul
season
transmiss
rate
gener
epidem
curv
shape
similar
epidem
curv
zika
outbreak
brazil
diseas
introduc
commun
via
infecti
contact
main
popul
transmiss
occur
infect
individu
transmit
suscept
connect
commun
suscept
individu
daili
probabl
infect
infecti
neighbor
forc
infect
well
daili
extern
hazard
infect
main
popul
vari
preval
main
popul
diseas
natur
histori
follow
susceptibleexposedinfectioussymptomat
infectiousasymptomat
recov
sei
ia
r
model
estim
incub
infecti
period
zikalik
diseas
supplementari
tabl
vector
transmiss
directli
model
serial
interv
simul
diseas
shorter
zika
viru
diseas
symptomat
asymptomat
infect
assum
equal
infecti
whether
individu
infect
symptomat
asymptomat
individu
affect
probabl
becom
symptomat
baselin
paramet
model
assum
infect
vaccin
control
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
group
becom
symptomat
base
estim
proport
zika
infect
symptomat
epidem
vaccin
trial
simul
network
individu
group
five
rel
disconnect
commun
well
network
individu
one
larg
commun
individu
commun
enrol
long
trial
individu
random
vaccin
control
group
individu
enrol
trial
assum
infect
practic
might
requir
serolog
test
individu
prior
enrol
vaccin
leaki
mean
reduc
probabl
infect
upon
exposur
infecti
individu
daili
probabl
infect
vaccine
infecti
contact
assum
direct
leaki
multipl
vaccin
efficaci
ve
estim
seven
differ
approach
describ
tabl
trial
statu
ie
vaccin
control
explanatori
variabl
cox
proport
hazard
model
individu
never
infect
censor
end
trial
approach
assum
time
infect
known
exactli
day
even
asymptomat
infect
therefor
would
strictli
applic
frequent
test
perform
throughout
trial
approach
assum
infect
unobserv
asymptomat
infect
symptomat
infect
includ
cox
regress
infect
asymptomat
assum
surviv
without
infect
end
follow
latter
approach
lead
bia
estim
ve
see
figur
result
consid
five
addit
approach
interv
censor
cox
model
exact
day
infect
symptomat
individu
known
practic
would
laboratoryconfirm
asymptomat
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
infect
individu
interv
day
infect
rang
day
last
neg
serolog
test
day
first
posit
serolog
test
two
differ
interv
length
assess
determin
increas
frequenc
test
yield
precis
result
mention
method
assum
abil
serolog
test
distinguish
vaccin
acquir
immun
natur
acquir
immun
current
possibl
vaccinespathogen
result
network
five
commun
analyz
first
seven
approach
treat
five
commun
one
larg
commun
altern
account
potenti
heterogen
hazard
rate
commun
cox
model
approach
stratifi
commun
estim
approach
calcul
separ
within
commun
metaanalyz
use
inversevari
weight
empir
coverag
probabl
calcul
proport
simul
confid
interv
cover
true
ve
paramet
model
power
estim
proport
simul
p
null
hypothesi
estim
ve
greater
trial
also
simul
fewer
particip
assess
power
smaller
trial
addit
evalu
efficaci
vaccin
prevent
progress
symptom
vep
estim
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
final
assess
whether
result
hold
context
trial
paramet
trial
length
ve
proport
infect
individu
arm
trial
becom
symptomat
vari
r
code
analys
avail
http
figur
display
result
median
simul
singlecommun
network
show
ve
estim
seven
approach
describ
across
three
valu
basic
reproduct
number
expect
approach
return
accur
ve
estim
approach
return
estim
bias
toward
null
differenti
overestim
persontim
risk
wors
overestim
control
figur
bia
exacerb
increas
approach
return
estim
bias
toward
null
compar
true
valu
ve
also
expect
also
worsen
higher
level
approach
correct
bia
convert
riskbas
analysi
ratebas
analysi
interv
censor
cox
proport
hazard
model
approach
return
estim
approxim
equal
ve
input
model
approach
requir
fewer
resourc
would
necessit
cox
model
perfect
knowledg
infect
time
approach
use
three
one
serolog
test
respect
rather
frequent
monitor
infect
throughout
period
followup
approach
interv
censor
cox
model
test
end
trial
yield
result
approach
test
three
time
without
substanti
differ
coverag
probabl
power
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
set
consid
tabl
figur
thu
approach
yield
accur
estim
test
requir
end
trial
even
singl
serolog
test
could
resourceintens
approach
requir
test
trial
particip
end
trial
result
accur
estim
ve
figur
valu
consid
vep
tabl
valu
test
trial
particip
end
trial
substanti
reduc
requir
resourc
howev
number
case
low
supplementari
tabl
sampl
accur
estim
vep
approach
less
effici
other
mani
set
consid
ie
wider
confid
interv
see
supplementari
tabl
approach
work
trial
conduct
one
larg
commun
trial
conduct
disconnect
commun
recent
malaria
trial
trial
commun
increas
heterogen
bia
heterogen
hazard
rate
like
pronounc
method
account
heterogen
stratif
metaanalys
incorpor
random
effect
therefor
use
although
number
case
low
method
may
imprecis
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
approach
requir
substanti
fewer
resourc
estim
ve
vep
approach
accur
approach
particip
must
test
begin
trial
ensur
expos
immun
includ
preexist
immun
trial
would
reduc
total
number
overal
case
thu
power
limit
abil
draw
statist
signific
conclus
vaccin
effect
challeng
howev
limit
diseas
high
proport
mild
asymptomat
infect
prior
immun
would
reduc
power
trial
addit
distinguish
natur
vaccinederiv
immun
challeng
especi
begin
outbreak
emerg
infecti
diseas
much
known
serolog
test
like
earli
stage
develop
therefor
invest
diagnost
develop
also
critic
ensur
accur
estim
final
mani
simplifi
assumpt
made
includ
complet
ascertain
infecti
case
perfect
sensit
specif
diagnost
test
compar
infect
vaccine
infect
control
estim
vep
identifi
method
accur
estim
ve
vep
requir
serolog
test
trial
particip
end
trial
acquir
serolog
endpoint
sampl
yield
unbias
ve
estim
significantli
reduc
requir
resourc
parameter
zikalik
diseas
method
exact
paramet
describ
meant
repres
particular
epidem
context
mere
serv
guid
think
accur
estim
import
endpoint
vaccin
trial
differ
set
limit
resourc
inform
r
code
simpl
model
readili
modifi
reflect
diseas
vaccineand
settingspecif
paramet
identifi
resourcepreserv
method
import
design
trial
diseas
high
proport
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
asymptomat
mild
infect
especi
case
still
infecti
understand
potenti
sourc
bia
differ
approach
allow
accur
estim
epidem
set
ccbynd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
c
imput
data
set
analyz
approach
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
peopl
infect
therefor
peopl
incorrectli
still
perceiv
risk
control
group
vaccin
group
appar
incid
underestim
control
vaccin
group
lead
bia
toward
null
bia
exacerb
increas
peopl
control
group
becom
infect
still
perceiv
risk
time
post
random
person
time
atrisk
control
overestim
factor
e
q
r
mn
u
mn
v
rel
vaccin
group
cumul
hazard
time
p
symptomat
proport
control
z
efficaci
vaccin
infect
diseas
given
infect
respect
greater
nonneg
vep
posit
ve
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
ve
estim
baselin
paramet
five
commun
network
analyz
one
larg
commun
estim
vaccin
efficaci
suscept
infect
ve
use
seven
differ
method
across
three
valu
baselin
paramet
five
commun
network
analyz
one
larg
commun
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
